Lotus Pharmaceutical Co., Ltd.(TW:1795)
NT$156.00-10.50 (-6.31%)
TW:1795
Lotus Pharmaceutical Co., Ltd. financials statements
NT$156.00
At close:-10.50 (-6.31%)
Lotus Pharmaceutical Co., Ltd. (1795) Income Statement
Lotus Pharmaceutical Co., Ltd. Income Statement
Last quarter (Q2 2026), Lotus Pharmaceutical Co., Ltd.'s total revenue was NT$8.81B, an increase of 85.56% from the same quarter last year. In Q2, Lotus Pharmaceutical Co., Ltd.'s net income was NT$642.25M. See Lotus Pharmaceutical Co., Ltd.’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| NT$ 20.51B | NT$ 18.58B | NT$ 16.96B | NT$ 14.63B | NT$ 12.65B | |
| NT$ 10.64B | NT$ 10.92B | NT$ 9.38B | NT$ 7.81B | NT$ 5.64B | |
| NT$ 6.01B | NT$ 4.91B | NT$ 4.48B | NT$ 3.70B | NT$ 3.31B | |
| Depreciation and Amortization | NT$ 1.54B | NT$ 1.28B | NT$ 1.21B | NT$ 936.87M | NT$ 759.38M |
| NT$ 7.44B | NT$ 8.21B | NT$ 6.87B | NT$ 5.26B | NT$ 2.93B | |
| NT$ 5.90B | NT$ 6.02B | NT$ 4.90B | NT$ 4.32B | NT$ 2.20B | |
| NT$ -178.13M | NT$ 339.60M | NT$ 199.98M | NT$ -379.13M | NT$ -331.08M | |
| NT$ 5.72B | NT$ 6.36B | NT$ 5.10B | NT$ 3.94B | NT$ 1.87B | |
| NT$ 4.72B | NT$ 5.07B | NT$ 4.11B | NT$ 3.02B | NT$ 1.40B | |
| Per Share Metrics | |||||
| Basic EPS | NT$ 18.14 | NT$ 19.35 | NT$ 15.72 | NT$ 11.59 | NT$ 5.50 |
| Diluted EPS | NT$ 18.04 | NT$ 19.26 | NT$ 15.67 | NT$ 11.54 | NT$ 5.47 |
| Weighted Average Shares Outstanding | 260.26M | 261.85M | 261.17M | 260.55M | 255.17M |
| Weighted Average Shares Outstanding (Diluted) | 261.64M | 263.40M | 262.02M | 261.68M | 256.69M |
Currency in TWD
